• World
    • Africa
    • Asia Pacific
    • Central & South Asia
    • Europe
    • Latin America & Caribbean
    • Middle East & North Africa
    • North America
  • Coronavirus
  • Politics
    • US Election
    • US politics
    • Joe Biden
    • Brexit
    • European Union
    • India
    • Arab world
  • Economics
    • Finance
    • Eurozone
    • International Trade
  • Business
    • Entrepreneurship
    • Startups
    • Technology
  • Culture
    • Entertainment
    • Music
    • Film
    • Books
    • Travel
  • Environment
    • Climate change
    • Smart cities
    • Green Economy
  • Global Change
    • Education
    • Refugee Crisis
    • International Aid
    • Human Rights
  • International Security
    • ISIS
    • War on Terror
    • North Korea
    • Nuclear Weapons
  • Science
    • Health
  • 360 °
  • The Interview
  • In-Depth
  • Insight
  • Quick Read
  • Video
  • Podcasts
  • Interactive
  • My Voice
  • About
  • FO Store
Sections
  • World
  • Coronavirus
  • Politics
  • Economics
  • Business
  • Culture
  • Sign Up
  • Login
  • Publish

Make Sense of the world

Unique insight from 2,000+ contributors in 80+ Countries

Close

When It Comes to Investing, a Company’s History Is Key

Lord Byron’s adage, “The best prophet of the future is the past,” applies to investing as well.
By Sunil Asnani • Feb 11, 2020
Business news, investment news, tips for investors, how to invest, fundamental investment, pharmaceutical industry, emerging market investments, how to invest in emerging markets, how to pick a company to invest in, how to invest successfully

© Tashatuvango / Shutterstock

Never did I realize growing up that the subject I hated most would prove to be the most useful. No, I am not speaking about mathematics. Luckily, I was rather decent at the subject that many of my friends dreaded. The subject that I feared was none other than history. With its innumerable dates of battles and names of kings, it seemed not only boring but also terrifying when tests came around.

Now that I don’t face the pressure to memorize for tests, I have learned to love history. In fact, the first thing I do before investing in a company is study its past. This exercise gives me clarity on the quality of the company’s business and the capabilities of its leadership, the two most important drivers of value creation and stock market performance. I have come to believe that reconstructing and understanding a company’s history forms the very first principle of fundamental investing.

A Bad History

As an investor, I have analyzed hundreds of companies. On one occasion, I zeroed in on an Indian pharmaceutical company. On paper, it looked impressive. The company was growing rapidly, it had high profitability and an impressive pipeline of drugs that it was planning to launch in developed markets. I sought a meeting with senior management, and the chief financial officer briefed me about the company.

The CFO spun me a tale of his company’s rapid growth. He described the acquisition of several businesses in many geographies. I asked the gentleman questions about each acquisition. I wanted to know the rationale for each acquisition. I wanted to know how things transpired after the acquisition. Did the actual synergies turn out to be less or more than the anticipated ones? What did the CFO and his colleagues learn from each acquisition?


How to Keep Your Business in Sync With a Changing World

READ MORE


During my conversation with the CFO, I realized that the management team put a premium on growing rapidly. Mergers and acquisitions were its favored method and had become second nature to the company. However, the M&A strategy seemed to be poorly thought through. Many of the past acquisitions by the company had not worked out well. More importantly, the management team had not really learned from its mistakes.

I concluded that the senior management was incentivized to show top-line growth, which in the investment world refers to a company’s revenues or gross sales. However, sustainable and profitable growth is what matters and the management team did not seem to be focused on it. There was another fly in the ointment. The company was not developing any core competency to distinguish itself from its peers. It was clear that more focused competitors would one day eat its lunch, so I passed on the opportunity to invest in the company. It is a decision that time has since vindicated.

A Good History

In one of my fishing-for-investment expeditions, I ran into yet another pharmaceutical company with relatively small market capitalization. In investor speak, I came across a small cap pharma company exporting to an emerging market. Normally, such markets are sketchy high receivables, the term accountants use for bills due from a company’s customers. In emerging markets, not only does it take a long time to collect receivables, but there is also a high default rate because some customers refuse or are unable to pay.

The small cap pharma company had piqued my fancy because it had negative working capital — a term investors use for the capital a business needs for its day-to-day operations. The company had negative working capital because its customers were paying in advance before getting their drugs. Such a phenomenon is unheard of. Therefore, I had many questions for the founder who turned out to be a poor communicator prone to going off on tangents. I had to constantly drag him back to the issues in question.

As usual, the most important issue for me was the founder’s and his company’s history. I wanted to learn how the company began, how it evolved, and why its market capital was a few hundred million dollars instead of a few billion. After all, the company had been listed on the stock market for 20 years. What the founder told me is the most fascinating story I have ever heard.

It turned out that the founder listed the company on the stock exchange because he had no money to set up his first factory. I almost fell out of my chair when I heard this. As an investor, I would have expected the founder to go to venture capitalists or private equity shops. Approaching a bank for a loan was another possibility that I could countenance. However, going to the public market right from the get go is something that never occurred to me.

The founder calmly pointed out to me that my assumptions were flawed. Two decades ago, there was no venture capital or private equity in his country, and bank loans were expensive for small operators. Often, businesses had to bribe bank managers as well. In contrast, accessing capital through the stock market was cheaper. Of course, the downside was that the founder had to dilute his equity stake.

logo

Make Sense of the World

Unique insight from 2,000+ contributors in 80+ Countries

Make Sense of the World
Unique insights from 2000+ contributors in 80+ countries

Listing the company on the stock market was only the first hurdle for the founder. It transpired that he had the wrong partners. After an initial growth phase, the company hit choppy waters. Overseas distributors simply did not pay the money they owed, causing the company in turn to default on its debts. This was a time when this extraordinary company went through a near-death moment. The partners dropped out and creditors turned on the screws. If the founder was a lesser man, he would have thrown in the towel. Instead, he moved to Africa.

On a new continent, this intrepid entrepreneur set up a restaurant. Many people from his country came there to eat. Among his customers, he identified those who could be clients for his pharmaceutical business. The founder started selling directly to them, cutting out all middlemen. Soon, these new customers brought in enough cash to support the pharma company’s operations. The founder then closed the restaurant and went back full time to his pharmaceuticals business.

After Africa, the founder eyed Latin America. Here again, he found that distributors often paid late or did not pay at all. So, he found some poor teenagers with fire in their bellies in his country and paid for their Spanish lessons. They went on to become his distributors and partners. Today, they pay him in advance for his drugs, eliminating much of his business risk.

The history of the founder and his company taught me a few business lessons that I had failed to learn either at Wharton or McKinsey. First, fire in the belly matters more than polish when it comes to entrepreneurship. It is better to invest in a founder who can fall off the saddle and then climb back again instead of someone who wears a nice suit and speaks in smooth cadences.

Second, in the pharmaceutical business, it is not just research that matters. Distribution is key, especially in those emerging markets where life is a bit rough, laws often exist only on paper and business operates only on trust. Finally, the financials of a company only make sense when investors understand its fundamentals. Only then can they model the future and make prudent decisions.

The views expressed in this article are the author’s own and do not necessarily reflect Fair Observer’s editorial policy.

Share Story
CategoriesBusiness, Entrepreneurship Tagsbusiness news, business tips, doing business in emerging markets, how to invest, India pharmaceutical industry, investing in emerging markets, investing news, tips for investing, tips for investing in emerging markets, which companies should I invest in
Join our network of more than 2,000 contributors to publish your perspective, share your story and shape the global conversation. Become a Fair Observer and help us make sense of the world.

Fair Observer Recommends

YouTube Shows Its Concern for My Sanity YouTube Shows Its Concern for My Sanity
By Peter Isackson • Mar 30, 2021
Cults Have Conquered Wall Street Cults Have Conquered Wall Street
By Peter Isackson • Feb 19, 2021
Why Listening and Learning Come Before Strategy Why Listening and Learning Come Before Strategy
By KnowledgeWharton • Aug 31, 2020

Post navigation

Previous PostPrevious Michael Bloomberg’s Buy-In to Getting Elected
Next PostNext In India, Women Entrepreneurs Are Still Outliers
Subscribe
Register for $9.99 per month and become a member today.
Publish
Join our community of more than 2,500 contributors to publish your perspective, share your narrative and shape the global discourse.
Donate
We bring you perspectives from around the world. Help us to inform and educate. Your donation is tax-deductible.

Explore

  • About
  • Authors
  • FO Store
  • FAQs
  • Republish
  • Privacy Policy
  • Terms of Use
  • Contact

Regions

  • Africa
  • Asia Pacific
  • Central & South Asia
  • Europe
  • Latin America & Caribbean
  • Middle East & North Africa
  • North America

Topics

  • Politics
  • Economics
  • Business
  • Culture
  • Environment
  • Global Change
  • International Security
  • Science

Sections

  • 360°
  • The Interview
  • In-Depth
  • Insight
  • Quick Read
  • Video
  • Podcasts
  • Interactive
  • My Voice

Daily Dispatch


© Fair Observer All rights reserved
We Need Your Consent
We use cookies to give you the best possible experience. Learn more about how we use cookies or edit your cookie preferences. Privacy Policy. My Options I Accept
Privacy & Cookies Policy

Edit Cookie Preferences

The Fair Observer website uses digital cookies so it can collect statistics on how many visitors come to the site, what content is viewed and for how long, and the general location of the computer network of the visitor. These statistics are collected and processed using the Google Analytics service. Fair Observer uses these aggregate statistics from website visits to help improve the content of the website and to provide regular reports to our current and future donors and funding organizations. The type of digital cookie information collected during your visit and any derived data cannot be used or combined with other information to personally identify you. Fair Observer does not use personal data collected from its website for advertising purposes or to market to you.

As a convenience to you, Fair Observer provides buttons that link to popular social media sites, called social sharing buttons, to help you share Fair Observer content and your comments and opinions about it on these social media sites. These social sharing buttons are provided by and are part of these social media sites. They may collect and use personal data as described in their respective policies. Fair Observer does not receive personal data from your use of these social sharing buttons. It is not necessary that you use these buttons to read Fair Observer content or to share on social media.

 
Necessary
Always Enabled

These cookies essential for the website to function.

Analytics

These cookies track our website’s performance and also help us to continuously improve the experience we provide to you.

Performance
Uncategorized

This cookie consists of the word “yes” to enable us to remember your acceptance of the site cookie notification, and prevents it from displaying to you in future.

Preferences
Save & Accept